PT-141
A central-nervous-system melanocortin agonist studied specifically for its role in female sexual response research. PT-141 is one of the most-targeted peptides in women’s libido science.
A peptide developed for women’s biology.
PT-141 (bremelanotide) is a synthetic peptide derived from research into melanocortin receptor pathways. Unlike libido interventions that work through vascular mechanisms, PT-141 acts on the central nervous system — the brain itself — where the earliest signals of sexual interest originate.
For women, this central mechanism is the entire reason PT-141 became significant. The vast majority of libido research has historically focused on male physiology and vascular response. PT-141 emerged from research that recognized female sexual function isn’t primarily a vascular problem — it’s a neurological one.
Published research has documented PT-141’s effects on subjective sexual desire, arousal, and the brain’s response to sexual cues. Bremelanotide has also been the subject of FDA-approved clinical research for hypoactive sexual desire disorder in premenopausal women, making it one of the more well-characterized peptides in women’s sexual health literature.
When research finally caught up to women.
Centrally Acting Mechanism
Studied in Premenopausal Women
Beyond Vascular Response
Independently Tested. Verified by Batch.
Labeled amount per vial
Questions.
Research Use Only
